Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Multimodal imaging of hair follicle bulge-derived stem cells in a mouse model of traumatic brain injury.

Schomann T, Iljas JD, Que I, Li Y, Suidgeest E, Cruz LJ, Frijns JHM, Chan A, Löwik CMWG, Huisman MA, Mezzanotte L.

Cell Tissue Res. 2020 Feb 8. doi: 10.1007/s00441-020-03173-1. [Epub ahead of print]

PMID:
32036485
2.

Gold nanoparticle based double-labeling of melanoma extracellular vesicles to determine the specificity of uptake by cells and preferential accumulation in small metastatic lung tumors.

Lara P, Palma-Florez S, Salas-Huenuleo E, Polakovicova I, Guerrero S, Lobos-Gonzalez L, Campos A, Muñoz L, Jorquera-Cordero C, Varas-Godoy M, Cancino J, Arias E, Villegas J, Cruz LJ, Albericio F, Araya E, Corvalan AH, Quest AFG, Kogan MJ.

J Nanobiotechnology. 2020 Jan 23;18(1):20. doi: 10.1186/s12951-020-0573-0.

3.

Photodynamic cancer therapy enhances accumulation of nanoparticles in tumor-associated myeloid cells.

Huis In 't Veld RV, Ritsma L, Kleinovink JW, Que I, Ossendorp F, Cruz LJ.

J Control Release. 2019 Dec 31;320:19-31. doi: 10.1016/j.jconrel.2019.12.052. [Epub ahead of print]

4.

Design, construction, and biological testing of an implantable porous trilayer scaffold for repairing osteoarthritic cartilage.

Campos Y, Sola FJ, Almirall A, Fuentes G, Eich C, Que I, Chan A, Kaijzel E, Tabata Y, Quintanilla L, Rodríguez-Cabello JC, Cruz LJ.

J Tissue Eng Regen Med. 2019 Dec 11. doi: 10.1002/term.3001. [Epub ahead of print]

PMID:
31826327
5.

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.

Da Silva CG, Camps MGM, Li TMWY, Zerrillo L, Löwik CW, Ossendorp F, Cruz LJ.

Theranostics. 2019 Aug 21;9(22):6485-6500. doi: 10.7150/thno.34429. eCollection 2019.

6.

Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines.

Da Silva CG, Camps MGM, Li TMWY, Chan AB, Ossendorp F, Cruz LJ.

Biomaterials. 2019 Nov;220:119417. doi: 10.1016/j.biomaterials.2019.119417. Epub 2019 Aug 7.

PMID:
31419588
7.

pH-responsive poly(lactide-co-glycolide) nanoparticles containing near-infrared dye for visualization and hyaluronic acid for treatment of osteoarthritis.

Zerrillo L, Que I, Vepris O, Morgado LN, Chan A, Bierau K, Li Y, Galli F, Bos E, Censi R, Di Martino P, van Osch GJVM, Cruz LJ.

J Control Release. 2019 Sep 10;309:265-276. doi: 10.1016/j.jconrel.2019.07.031. Epub 2019 Jul 27.

PMID:
31362078
8.

Targeting Polymeric Nanobiomaterials as a Platform for Cartilage Tissue Engineering.

García-Couce J, Almirall A, Fuentes G, Kaijzel E, Chan A, Cruz LJ.

Curr Pharm Des. 2019;25(17):1915-1932. doi: 10.2174/1381612825666190708184745.

PMID:
31298149
9.

Environmentally compatible bioconjugated gold nanoparticles as efficient contrast agents for inflammation-induced cancer imaging.

Garcia VB, de Carvalho TG, da Silva Gasparotto LH, da Silva HFO, de Araújo AA, Guerra GCB, Schomann T, Cruz LJ, Chan AB, de Araújo Júnior RF.

Nanoscale Res Lett. 2019 May 17;14(1):166. doi: 10.1186/s11671-019-2986-y.

10.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG.

Molecules. 2019 May 12;24(9). pii: E1825. doi: 10.3390/molecules24091825.

11.

Tissue Engineering: An Alternative to Repair Cartilage.

Campos Y, Almirall A, Fuentes G, Bloem HL, Kaijzel EL, Cruz LJ.

Tissue Eng Part B Rev. 2019 Aug;25(4):357-373. doi: 10.1089/ten.TEB.2018.0330.

PMID:
30913997
12.

Assembly of upconversion nanophotosensitizer in vivo to achieve scatheless real-time imaging and selective photodynamic therapy.

Feng Y, Wu Y, Zuo J, Tu L, Que I, Chang Y, Cruz LJ, Chan A, Zhang H.

Biomaterials. 2019 May;201:33-41. doi: 10.1016/j.biomaterials.2019.02.015. Epub 2019 Feb 13.

PMID:
30784770
13.

A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function.

Kleinovink JW, Mezzanotte L, Zambito G, Fransen MF, Cruz LJ, Verbeek JS, Chan A, Ossendorp F, Löwik C.

Front Immunol. 2019 Jan 8;9:3097. doi: 10.3389/fimmu.2018.03097. eCollection 2018.

14.

Sustained maximal inspiration has similar effects compared to incentive spirometers.

Mendes LPS, Teixeira LS, da Cruz LJ, Vieira DSR, Parreira VF.

Respir Physiol Neurobiol. 2019 Mar;261:67-74. doi: 10.1016/j.resp.2019.01.006. Epub 2019 Jan 14.

PMID:
30654164
15.

Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.

Chung CK, Da Silva CG, Kralisch D, Chan A, Ossendorp F, Cruz LJ.

J Control Release. 2018 Sep 10;285:56-66. doi: 10.1016/j.jconrel.2018.07.011. Epub 2018 Jul 6. Review.

PMID:
30008371
16.

Spherical neutral gold nanoparticles improve anti-inflammatory response, oxidative stress and fibrosis in alcohol-methamphetamine-induced liver injury in rats.

de Carvalho TG, Garcia VB, de Araújo AA, da Silva Gasparotto LH, Silva H, Guerra GCB, de Castro Miguel E, de Carvalho Leitão RF, da Silva Costa DV, Cruz LJ, Chan AB, de Araújo Júnior RF.

Int J Pharm. 2018 Sep 5;548(1):1-14. doi: 10.1016/j.ijpharm.2018.06.008. Epub 2018 Jun 7.

PMID:
29886101
17.

Customizing poly(lactic-co-glycolic acid) particles for biomedical applications.

Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M.

Acta Biomater. 2018 Jun;73:38-51. doi: 10.1016/j.actbio.2018.04.006. Epub 2018 Apr 11. Review.

18.

Near Infrared Light Sensitive Ultraviolet-Blue Nanophotoswitch for Imaging-Guided "Off-On" Therapy.

Zuo J, Tu L, Li Q, Feng Y, Que I, Zhang Y, Liu X, Xue B, Cruz LJ, Chang Y, Zhang H, Kong X.

ACS Nano. 2018 Apr 24;12(4):3217-3225. doi: 10.1021/acsnano.7b07393. Epub 2018 Mar 2.

PMID:
29489327
19.

Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK/Akt/mTOR pathway and EGFR/FAAD proteins.

De Araújo RF Jr, Pessoa JB, Cruz LJ, Chan AB, De Castro Miguel E, Cavalcante RS, Brito GAC, Silva HFO, Gasparotto LHS, Guedes PMM, Araújo AA.

Int J Oncol. 2018 Jan;52(1):189-200. doi: 10.3892/ijo.2017.4179. Epub 2017 Oct 27.

PMID:
29115423
20.

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

Ghinnagow R, De Meester J, Cruz LJ, Aspord C, Corgnac S, Macho-Fernandez E, Soulard D, Fontaine J, Chaperot L, Charles J, Soncin F, Mami-Chouaib F, Plumas J, Faveeuw C, Trottein F.

Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017.

21.

The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ.

Cancer Chemother Pharmacol. 2017 Nov;80(5):881-894. doi: 10.1007/s00280-017-3427-1. Epub 2017 Sep 8. Review.

22.

Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Ghinnagow R, Cruz LJ, Macho-Fernandez E, Faveeuw C, Trottein F.

Front Immunol. 2017 Jul 27;8:879. doi: 10.3389/fimmu.2017.00879. eCollection 2017. Review.

23.

Editorial: Targeting the Brain with Nanomedicine: Diagnostics, Prevention and Treatment.

Cruz LJ.

Curr Pharm Des. 2017;23(13):1877-1878. doi: 10.2174/1381612823999170201160007. No abstract available.

PMID:
28701140
24.

Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines.

Rueda F, Eich C, Cordobilla B, Domingo P, Acosta G, Albericio F, Cruz LJ, Domingo JC.

Immunobiology. 2017 Nov;222(11):989-997. doi: 10.1016/j.imbio.2017.06.002. Epub 2017 Jun 10.

PMID:
28624137
25.

Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells.

Tüysüz N, van Bloois L, van den Brink S, Begthel H, Verstegen MM, Cruz LJ, Hui L, van der Laan LJ, de Jonge J, Vries R, Braakman E, Mastrobattista E, Cornelissen JJ, Clevers H, Ten Berge D.

Nat Commun. 2017 Mar 6;8:14578. doi: 10.1038/ncomms14578.

26.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9.

PMID:
28181470
27.

Traumatic Brain Injury: Preclinical Imaging Diagnostic(s) and Therapeutic Approaches.

Kaijzel EL, van Beek ER, Stammes MA, Que I, Chan AB, Lowik CWGM, Cruz LJ.

Curr Pharm Des. 2017;23(13):1909-1915. doi: 10.2174/1381612823666170116141116. Review.

PMID:
28093969
28.

The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis.

In't Veld RH, Da Silva CG, Kaijzel EL, Chan AB, Cruz LJ.

Curr Pharm Des. 2017;23(13):1985-1992. doi: 10.2174/1381612822666161221151900. Review.

PMID:
28003012
29.

Targeting the Brain with Nanomedicine.

Rueda F, Cruz LJ.

Curr Pharm Des. 2017;23(13):1879-1896. doi: 10.2174/1381612822666161221153228. Review.

PMID:
28003011
30.

Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging.

Stammes MA, Knol-Blankevoort VT, Cruz LJ, Feitsma HR, Mezzanotte L, Cordfunke RA, Sinisi R, Dubikovskaya EA, Maeda A, DaCosta RS, Bierau K, Chan A, Kaijzel EL, Snoeks TJ, van Beek ER, Löwik CW.

Mol Imaging Biol. 2016 Dec;18(6):905-915.

31.

Proteome Based Construction of the Lymphocyte Function-Associated Antigen 1 (LFA-1) Interactome in Human Dendritic Cells.

Eich C, Lasonder E, Cruz LJ, Reinieren-Beeren I, Cambi A, Figdor CG, Buschow SI.

PLoS One. 2016 Feb 18;11(2):e0149637. doi: 10.1371/journal.pone.0149637. eCollection 2016.

32.

Combinatorial prospects of nano-targeted chemoimmunotherapy.

Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ.

Biomaterials. 2016 Mar;83:308-20. doi: 10.1016/j.biomaterials.2016.01.006. Epub 2016 Jan 9. Review.

PMID:
26796043
33.

Effect of PLGA NP size on efficiency to target traumatic brain injury.

Cruz LJ, Stammes MA, Que I, van Beek ER, Knol-Blankevoort VT, Snoeks TJA, Chan A, Kaijzel EL, Löwik CWGM.

J Control Release. 2016 Feb 10;223:31-41. doi: 10.1016/j.jconrel.2015.12.029. Epub 2015 Dec 18.

PMID:
26708021
34.

Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

Kleinovink JW, van Driel PB, Snoeks TJ, Prokopi N, Fransen MF, Cruz LJ, Mezzanotte L, Chan A, Löwik CW, Ossendorp F.

Clin Cancer Res. 2016 Mar 15;22(6):1459-68. doi: 10.1158/1078-0432.CCR-15-0515. Epub 2015 Nov 6.

35.

Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models.

Xie B, Stammes MA, van Driel PB, Cruz LJ, Knol-Blankevoort VT, Löwik MA, Mezzanotte L, Que I, Chan A, van den Wijngaard JP, Siebes M, Gottschalk S, Razansky D, Ntziachristos V, Keereweer S, Horobin RW, Hoehn M, Kaijzel EL, van Beek ER, Snoeks TJ, Löwik CW.

Oncotarget. 2015 Nov 17;6(36):39036-49. doi: 10.18632/oncotarget.5498.

36.

PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI.

Srinivas M, Tel J, Schreibelt G, Bonetto F, Cruz LJ, Amiri H, Heerschap A, Figdor CG, de Vries IJ.

Nanomedicine (Lond). 2015;10(15):2339-48. doi: 10.2217/NNM.15.76. Epub 2015 Aug 7.

PMID:
26251876
37.

A tyrosine-containing analog of mu-conotoxin GIIIA as ligand in the receptor binding assay for paralytic shellfish poisons.

Mendoza AD, Sombrito EZ, Cruz LJ.

Toxicon. 2015 Jun 1;99:95-101. doi: 10.1016/j.toxicon.2015.03.016. Epub 2015 Mar 26.

PMID:
25817004
38.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F.

Biomaterials. 2015 Feb;40:88-97. doi: 10.1016/j.biomaterials.2014.10.053. Epub 2014 Nov 26.

PMID:
25465442
39.

Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism.

Cruz LJ, Tacken PJ, Zeelenberg IS, Srinivas M, Bonetto F, Weigelin B, Eich C, de Vries IJ, Figdor CG.

Mol Pharm. 2014 Dec 1;11(12):4299-313. doi: 10.1021/mp400717r. Epub 2014 Oct 24.

PMID:
25290882
40.

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.

Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CW, Ossendorp F.

J Control Release. 2014 Oct 28;192:209-18. doi: 10.1016/j.jconrel.2014.07.040. Epub 2014 Jul 25.

PMID:
25068703
41.

Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.

Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C.

J Immunol. 2014 Jul 15;193(2):961-9. doi: 10.4049/jimmunol.1303029. Epub 2014 Jun 9.

42.

Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.

Cruz LJ, Rueda F, Simón L, Cordobilla B, Albericio F, Domingo JC.

Nanomedicine (Lond). 2014 Apr;9(4):435-49. doi: 10.2217/NNM.13.66.

PMID:
24910875
43.

Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion.

Tel J, Sittig SP, Blom RA, Cruz LJ, Schreibelt G, Figdor CG, de Vries IJ.

J Immunol. 2013 Nov 15;191(10):5005-12. doi: 10.4049/jimmunol.1300787. Epub 2013 Oct 14.

44.

Chemical fingerprinting and phylogenetic mapping of saponin congeners from three tropical holothurian sea cucumbers.

Bondoc KG, Lee H, Cruz LJ, Lebrilla CB, Juinio-Meñez MA.

Comp Biochem Physiol B Biochem Mol Biol. 2013 Nov-Dec;166(3-4):182-93. doi: 10.1016/j.cbpb.2013.09.002. Epub 2013 Sep 12. Erratum in: Comp Biochem Physiol B Biochem Mol Biol. 2014 Sep;175:39-40.

PMID:
24036426
45.

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA, Janssen G, Franken K, Cruz LJ, Tromp A, Oostendorp J, van der Burg SH, Ossendorp F, Melief CJ.

Eur J Immunol. 2013 Oct;43(10):2554-65. doi: 10.1002/eji.201343324. Epub 2013 Aug 5.

46.

Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.

Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ.

Clin Cancer Res. 2013 Mar 15;19(6):1525-33. doi: 10.1158/1078-0432.CCR-12-1879. Epub 2013 Feb 4.

47.

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ.

Blood. 2013 Jan 17;121(3):459-67. doi: 10.1182/blood-2012-06-435644. Epub 2012 Dec 4.

PMID:
23212525
48.

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Review.

PMID:
23148541
49.

Targeting nanoparticles to dendritic cells for immunotherapy.

Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG.

Methods Enzymol. 2012;509:143-63. doi: 10.1016/B978-0-12-391858-1.00008-3. Review.

PMID:
22568905
50.

Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.

Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG.

Biomaterials. 2012 Jun;33(16):4229-39. doi: 10.1016/j.biomaterials.2012.02.036. Epub 2012 Mar 10.

PMID:
22410170

Supplemental Content

Support Center